Clinical Trial Update: Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of a multi-target recombinant vaccine targeting CEA/MUC1/Brachyury in advanced cancer completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms
• Prostate Cancer

Drugs mentioned

• Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasms, Prostate Cancer | Phase 1 | Status: COMPLETED | Results posted: 2019-12-23